Objective: Use of antenatal magnesium sulfate (MgSO 4) may reduce cerebral palsy in
infants born very preterm. Low systemic blood flow in the first day in very preterm infants has …

Objectives. To investigate whether antenatal magnesium sulfate (MgSO4) exposure has an
influence on cerebral blood flow and systemic hemodynamics in preterm infants during the …

Objectives. To investigate whether in utero exposure to magnesium sulfate (MgSO4) was
associated with a lower prevalence of cerebral palsy (CP) in infants born weighing< 1500 g …

Magnesium sulfate (MgSO 4) has been shown to prevent cerebral palsy among children
born to women at high risk of early preterm delivery. Three large, randomized placebo …

Background Research suggests that fetal exposure to magnesium sulfate before preterm
birth might reduce the risk of cerebral palsy. Methods In this multicenter, placebo-controlled …

Objective: The objective of this study is to investigate the effects of antenatal magnesium
sulfate (MgSO 4) on cerebral blood flow (CBF) velocities in preterm neonates. Study Design …

Magnesium sulfate (MgSO4) has been widely used in the perinatal arena for many decades.
It has been used for tocolysis in the US for more than 60 years. Estimations of MgSO4 use …

Cerebral palsy occurs in three to four infants per 1000 live births. Preterm birth prior to 34
weeks' gestation is a major risk factor. Five randomized controlled trials of antenatal …

Methods Subjects were newborn infants delivered at> or= 34 weeks of gestation whose
mothers received a minimum of 12 hours of intravenous MgSO4 therapy before delivery …

Three large, randomized placebo-controlled trials of antenatal magnesium sulfate (MgSO4)
for fetal neuroprotection have recently been conducted and reported. The results of these …